Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells

Nature Biotechnology

Volumn 31, Issue 7, 2013, Pages 630-637

  Taipale, Mikko ^a   Krykbaeva, Irina ^a   Whitesell, Luke ^a   Santagata, Sandro ^a,b   Zhang, Jianming ^c   Liu, Qingsong ^c   Gray, Nathanael S ^c   Lindquist, Susan ^a,d,e  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOSTERIC INHIBITOR; BROAD APPLICATION; CELLULAR CONTEXTS; DRUG-TARGET INTERACTIONS; HORMONE RECEPTORS; KINASE INHIBITORS; SMALL-MOLECULE BINDINGS; TUMOR XENOGRAFTS;

ENZYME INHIBITION; MOLECULES; SENSORS; TUMORS;

DRUG INTERACTIONS;

2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; CD37 ANTIGEN; CRIZOTINIB; DASATINIB; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; IMATINIB; SORAFENIB; TRAMETINIB;

ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; DRUG POTENCY; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THERMODYNAMICS; TUMOR XENOGRAFT;

ANIMALS; CELL CYCLE PROTEINS; DRUG APPROVAL; DRUG INTERACTIONS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MOLECULAR CHAPERONES; NEOPLASMS; PHOSPHOTRANSFERASES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ETS; PYRAZOLES; PYRIDINES; RECEPTOR, TRKC; REPRESSOR PROTEINS; SUBSTRATE SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880307149     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2620     Document Type: Article

References (46)

1. Taipale, M. et al. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 150, 987-1001 (2012).
2. Goldstein, D.M., Gray, N.S. & Zarrinkar, P.P. High-throughput kinase profiling as a platform for drug discovery. Nat. Rev. Drug Discov. 7, 391-397 (2008).
3. Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
4. Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005).
5. Davis, M.I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051 (2011).
6. Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523-20528 (2007).
7. Anastassiadis, T., Deacon, S.W., Devarajan, K., Ma, H. & Peterson, J.R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039-1045 (2011).
8. Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315 (2007).
9. Eck, M.J. & Manley, P.W. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Curr. Opin. Cell Biol. 21, 288-295 (2009).
10. Posy, S.L. et al. Trends in kinase selectivity: insights for target class-focused library screening. J. Med. Chem. 54, 54-66 (2011).
11. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044 (2007).
12. Patricelli, M.P. et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 18, 699-710 (2011).
13. Barrios-Rodiles, M. et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307, 1621-1625 (2005).
14. Shah, N.P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004).
15. O'Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401-412 (2009).
16. Waldron, T.T. & Murphy, K.P. Stabilization of proteins by ligand binding: application to drug screening and determination of unfolding energetics. Biochemistry 42, 5058-5064 (2003).
17. Vaughan, C.K. et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 23, 697-707 (2006).
18. Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506 (2010).
19. Yang, J. et al. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem. Biol. 18, 177-186 (2011).
20. Iacob, R.E., Zhang, J., Gray, N.S. & Engen, J.R. Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS ONE 6, e15929 (2011).
21. Xu, W. et al. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat. Struct. Mol. Biol. 12, 120-126 (2005).
22. Picard, D. Chaperoning steroid hormone action. Trends Endocrinol. Metab. 17, 229-235 (2006).
23. Couture, P., Theriault, C., Simard, J. & Labrie, F. Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology 132, 179-185 (1993).
24. Adcock, I.M., Nasuhara, Y., Stevens, D.A. & Barnes, P.J. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br. J. Pharmacol. 127, 1003-1011 (1999).
25. Gozgit, J.M. et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 11, 690-699 (2012).
26. Gozgit, J.M. et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol. Cancer Ther. 10, 1028-1035 (2011).
27. Dar, A.C. & Shokat, K.M. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu. Rev. Biochem. 80, 769-795 (2011).
28. Azam, M., Latek, R.R. & Daley, G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831-843 (2003).
29. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
30. Zou, H.Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417 (2007).
31. Lannon, C.L. & Sorensen, P.H. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin. Cancer Biol. 15, 215-223 (2005).
32. Orbach, D. et al. Infantile fibrosarcoma: management based on the European experience. J. Clin. Oncol. 28, 318-323 (2010).
33. Eguchi, M. et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 93, 1355-1363 (1999).
34. Kralik, J.M. et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn. Pathol. 6, 19 (2011).
35. Skalova, A. et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am. J. Surg. Pathol. 34, 599-608 (2010).
36. Okabe, M. et al. Megakaryocytic differentiation of a leukemic cell line, MC3, by phorbol ester: induction of glycoprotein IIb/IIIa and effects on expression of IL-6, IL-6 receptor, mpl and GATA genes. Leuk. Res. 19, 933-943 (1995).
37. Tognon, C. et al. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. Cancer Res. 61, 8909-8916 (2001).
38. Galkin, A.V. et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. USA 104, 270-275 (2007).
39. Gadd, S. et al. Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study. J. Pathol. 228, 119-130 (2012).
40. Chaires, J.B. Calorimetry and thermodynamics in drug design. Annu. Rev. Biophys. 37, 135-151 (2008).
41. Gong, Y. et al. An atlas of chaperone-protein interactions in Saccharomyces cerevisiae: implications to protein folding pathways in the cell. Mol. Syst. Biol. 5, 275 (2009).
42. Kerner, M.J. et al. Proteome-wide analysis of chaperonin-dependent protein folding in Escherichia coli. Cell 122, 209-220 (2005).
43. Mosse, Y.P. et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study. J. Clin. Oncol. Supplement Abstract 9500 (2012).
44. Novo, F.J., de Mendibil, I.O. & Vizmanos, J.L. TICdb: a collection of gene-mapped translocation breakpoints in cancer. BMC Genomics 8, 33 (2007).
45. Atanassov, I.I., Etchells, J.P. & Turner, S.R. A simple, flexible and efficient PCR-fusion/Gateway cloning procedure for gene fusion, site-directed mutagenesis, short sequence insertion and domain deletions and swaps. Plant Methods 5, 14 (2009).
46. Koh, E.Y., Chen, T. & Daley, G.Q. Novel retroviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res. 30, e142 (2002). Drug Discovery-Driving Medical Projects